<DOC>
	<DOCNO>NCT00283829</DOCNO>
	<brief_summary>The purpose study test interleukin-2 , drug stimulates immune system , use chemotherapy slow progression disease . We also want test best dose interleukin-2 use safely home . Interleukin-2 , abbreviate IL2 , naturally produce growth hormone immune cell body . It stimulate growth immune cell enhance ability fight infection cancer . In people cancer , immune cell typically suppress become even irradiation chemotherapy treatment . By give IL2 hope enhance immune system fight cancer well , control cancer growth shrink cancer .</brief_summary>
	<brief_title>Immunotherapy After Chemotherapy Patients With Hormone Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description>There two treatment phase study . But begin study , need find whether eligible study . You undergo follow procedure . - Medical history review physical exam - Blood test hematology , chemistry , PSA , immune assay ( approximately 4 tablespoon blood ) - EKG - CT scan abdomen pelvis bone scan - Complete pain questionnaire , quality life questionnaire , pain medication diary , symptom diary The initial treatment phase study consist chemotherapy drug give weekly . You receive 3 weekly chemotherapy treatment follow 1 week treatment . Three week treatment follow one week treatment consider 1 cycle , receive total 4 cycle chemotherapy 16-week period . Taxotere give intravenously clinic 1st day weekly treatment . Treatment taxotere currently accept treatment stage prostate cancer . Your doctor may recommend receive taxotere even participate study . During phase treatment , blood draw treatment week prior chemotherapy . You PSA draw every month ( week 5 , 9 , 13 ) . We ask complete pain questionnaire , quality life questionnaire , pain medication diary , symptom diary week 5 , 9 , 13 . Some question may personal , `` I satisfy sex life '' `` I worry die '' . You answer question want . You also physical exam begin 3rd cycle treatment ( week 9 ) . The second phase treatment program experimental part : immunotherapy IL2 . You assign receive one 4 dos IL2 . This test high dose IL2 subject receive without unacceptable side affect IL2 . You give shot IL2 skin twice day 5 day per week 3 week . During 3rd week treatment 2 day give high dose IL2 boost immune cell ( see diagram ) . The 4th week rest week receive treatment . One 4-week period IL2 treatment call cycle . You continue receive cycle IL2 treatment long cancer show growth . We teach administer IL2 home .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients age &gt; 18 year histological diagnosis prostate cancer Hormone refractory disease least 2 serial rise PSA castrate level testosterone ( &lt; 50ng/dL ) . Primary hormonal therapy continue . Patients must metastatic disease evidence soft tissue bony metastasis Patients ECOG performance status 0 , 1 , 2 Patients must preserve organ function Bilirubin &lt; ULN serum creatinine 1.5 x ULN , transaminases ( SGOT and/or SGPT ) may 2.5 x institutional upper limit normal ( ULN ) alkaline phosphatase ULN , alkaline phosphatase may 4 x ULN transaminases ULN . Patients must chronic steroid treatment least 2 week , pre/postchemotherapy steroid medication least 1 week Patients may receive Taxanes previously . Patients must able complete pain quality life scale . Ancillary treatment , bisphosphonate , pain medication allow , natural herbal , homeopathic supplement MGN3 allow . Absolute neutrophil count &gt; 1,500/mm3 , hemoglobin &gt; 8.0 g/dl , platelet count &gt; 100,000/mm3 . Men childbearing potential must willing consent use effective contraception treatment 12 month period thereafter . Patients chronic steroid medication Spine radiation therapy cord compression within 2 week study entry Concurrent use investigational therapy Prior immunotherapy IL2 alphainterferon within 30 day Peripheral neuropathy &gt; Grade 1 Other active malignancy , except nonmelanotic skin cancer Significant active medical illness psychosocial condition opinion investigator would preclude protocol treatment . Hypersensitivity drug formulate polysorbate80 Patients contraindication Coumadin aspirin .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Immunotherapy</keyword>
</DOC>